



**FRESENIUS  
KABI**

caring for life

# TauroSept<sup>®</sup>

Tough enough.

For prevention *and* treatment  
of catheter infections.<sup>1</sup>

This brochure does not replace TauroSept<sup>®</sup> instructions for use.  
TauroSept<sup>®</sup> intended use and references can be found on the back cover.




**Calea**

the heart of homecare



# TauroSept® catheter lock battles the intraluminal pathology associated with CRBSIs.<sup>1,2</sup>

Figure 1: TauroSept® mechanism of action.<sup>1,2</sup>  
For illustrative purposes only.



## ESPEN guidelines (2016)<sup>7</sup>

- Suggest catheter locking with taurolidine may be used to prevent central venous catheter-related infections in adults with intestinal failure.
- Heparin lock has been proven to be ineffective for prevention of catheter-related infections.

## BIFA (2019)<sup>8</sup>

- Recommend the prophylactic use of an antimicrobial lock (e.g. taurolidine) be considered for recurrent CRBSIs.


# TauroSept® - a proven antimicrobial agent with broad clinical experience in the prevention of CRBSIs.<sup>4, 9-11</sup>

➤ TauroSept® is more effective at inhibiting antimicrobial growth versus 1.34% taurolidine + 4% citrate and 1.34% taurolidine + 4% citrate + 500IU/ml heparin *in vitro*.<sup>9</sup>

Figure 2. Differences in growth of *S. aureus*, *C. glabrata* and *E.coli* *in vitro* with different dilutions of taurolidine-containing lock solutions as determined by measurement of optical density, every 30 minutes for 60 hours during incubation in media at 37°C.<sup>9</sup>


- **2% taurolidine (TauroSept®)**
- **1.34% taurolidine + 4% citrate (TauroLock™)**
- **1.34% taurolidine + 4% citrate + 500 IU/ml heparin (TauroLock™ - Hep 500)**
- **Phosphate buffered saline (PBS, control)**

## ***Staphylococcus aureus*** 50x dilution of test solutions



## ***Candida glabrata***


33x dilution of test solutions



Adapted from reference 9.

## ***Escherichia coli***

20x dilution of test solutions



✓ TauroSept® - over 10 years of real-world experience.<sup>10</sup>

✓ TauroSept® - comparable tolerability to normal saline lock in a clinical study.<sup>11</sup>





# TauroSept®

Tough enough.  
For prevention  
*and* treatment of  
catheter infections.



**Taurolidine, 2% strength.<sup>1</sup>**



**Broad-spectrum antimicrobial that  
battles the intraluminal biofilm.<sup>1,4</sup>**



**Over 10 years of real-world experience,<sup>10</sup>  
including clinical studies demonstrating  
efficacy,<sup>4,11</sup> in the prevention of CRBSIs.**

TauroSept® is a class III  
medical device according to  
MDD 93/42 EEC.<sup>1</sup>

TauroSept® is intended for installation in  
intravascular catheters between treatments in  
order to prevent bacterial and fungal growth  
leading to microbial infection in the catheter  
lumen, as well as to maintain device patency and  
to avoid staphylococcal-induced clotting of blood.  
TauroSept® can also be used as adjuvant  
treatment in infected catheters.<sup>1</sup>



**For further information about  
TauroSept®, or the aseptic  
compounding services provided  
by Calea UK Limited, please  
contact your local Calea  
Business Development Manager.**

Package size -  
box with 5 vials  
of 6ml or 10ml!<sup>1</sup>

## References

1. TauroSept®. Instructions for Use. Geistlich Pharma AG. June 2015.
2. Olthof ED, Versleijen MW, Huisman-de Waal G, Feuth T, Kievit W, Wanten GJ. Taurolidine lock is superior to heparin lock in the prevention of catheter related bloodstream infections and occlusions. PLoS One. 2014 Nov 7;9(11):e111216.
3. Donlan RM, Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002 Apr;15(2):167-93.
4. Bisseling TM, Willems MC, Versleijen MW, Hendriks JC, Visser RK, Wanten GJ. Taurolidine lock is highly effective in preventing catheter-related bloodstream infections in patients on home parenteral nutrition: a heparin-controlled prospective trial. Clin Nutr. 2010 Aug;29(4):464-8.
5. Blenkarn JI. Sustained anti-adherence activity of taurolidine (Taurolin) and noxythiolin (Noxyflex S) solutions. J Pharm Pharmacol. 1988 Jul;40(7):509-11.
6. Gorman SP, McCafferty DF, Woolfson AD, Jones DS. Reduced adherence of micro-organisms to human mucosal epithelial cells following treatment with Taurolin, a novel antimicrobial agent. J Appl Bacteriol. 1987 Apr;62(4):315-20.
7. Pironi L, Arends J, Bozzetti F, Cuerda C, Gillanders L, Jeppesen PB, Joly F, Kelly D, Lal S, Staun M, Szczepanek K, Van Gossum A, Wanten G, Schneider SM; Home Artificial Nutrition & Chronic Intestinal Failure Special Interest Group of ESPEN. ESPEN guidelines on chronic intestinal failure in adults. Clin Nutr. 2016 Apr;35(2):247-307.
8. British Intestinal Failure Alliance (BIFA). Management of Catheter Related Blood Stream Infections. January 2019. Available at <https://www.bapen.org.uk/pdfs/bifa/recommendations-on-management-of-crbsi.pdf> Accessed June 2019.
9. Olthof ED, Nijland R, Gülich AF, Wanten GJ. Microbicidal effects of various taurolidine containing catheter lock solutions. Clin Nutr. 2015 Apr;34(2):309-14.
10. Data on File. Geistlich Pharma AG. December 2017.
11. Wouters Y, Theilla M, Singer P, Tribler S, Jeppesen PB, Pironi L, Vinter-Jensen L, Rasmussen HH, Rahman F, Wanten GJA. Randomised clinical trial: 2% taurolidine versus 0.9% saline locking in patients on home parenteral nutrition. Aliment Pharmacol Ther. 2018 Aug;48(4):410-422.